Published in Medical Letter on the CDC and FDA, September 19th, 2004
For the fourth quarter of 2004, Pharmacyclics recorded a net loss of $7.3 million, or $0.38 per share, compared to a net loss of $7.5 million, or $0.46 per share, for the fourth quarter of 2003.
Research and development expenses remained constant at $6.2 million for the fourth quarter 2004 when compared to the fourth quarter of 2003, as the company continued enrolling patients in a randomized pivotal Phase 3 trial evaluating the efficacy and safety of Xcytrin (motexafin gadolinium) Injection for the treatment of brain metastases...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA